P.J. Popovic, CEO of Houston-based Rhythm, explains Renewable Energy Certificates work and their impact on Texas. Photo courtesy of Rhythm

We all know what renewable energy is — wind, solar, biomass, geothermal, hydropower — but how do you purchase it? It's invisible. Not to mention when energy from any source enters the electricity grid, there's no way to track all those electrons.

Renewable Energy Certificates have made it possible

Renewable Energy Certificates, or RECs, allow us to track your clean energy. Each individual REC represents one megawatt-hour of clean energy generated. And while a REC isn't technically electricity, it represents the clean energy going into the electricity grid—meaning homes and businesses claim their commitment to renewable energy if their electricity is supported by RECs.

It's also important to understand what a renewable energy certificate is not: an offset. An offset represents a metric ton of emissions avoided and a REC represents 1 MWh of clean energy generated. While each have similar goals, they are not quite the same thing.

Not all RECs are created equally

The market for RECs is fluid. Due to the growth of the renewable energy market, RECs have been oversupplied for years. This has created low prices and little-to-no financial advantage for the facilities that generate clean electricity (e.g., wind facilities, solar farms, hydro plants).

In Texas, the retail electricity market is inundated with renewable electricity claims said to be supported by RECs. The energy plan you sign up for might come from solar, wind, biomass, or even trash incineration, but the renewable energy facilities likely are coming from outside Texas, located in places like California, Canada, or elsewhere. While there's no wrong way to switch to renewable energy, supporting renewable energy sources inside Texas helps Texans move closer to being a more sustainable state.

Choosing Texas renewable energy plans and your actions do have a true, real-world impact more than ever before

Some critics have argued that REC-supported renewable energy plans don't meet the highest standard of sustainability arguing RECs are not foundational to the existence of renewable energy assets. In other words, they argue that RECs don't provide a material revenue source for renewable projects because they don't incentivize new developments of renewable facilities to be built.

When RECs were trading for less than a dollar, this was a valid argument. But that was then, and this is now.

In the last year alone, voluntary renewable energy certificate prices have skyrocketed and are now between $7 and $10 per MWh. This means RECs can now contribute up to 30 percent of a renewable facility's revenue. Naturally, this encourages more and more clean-energy facilities and clean-energy jobs to be created. A win-win.

What about Power Purchase Agreements?

A Power Purchase Agreement, or PPA, is a tad different than a REC. In a PPA, the developer of a renewable project (solar arrays at a solar farm, or turbines at a wind farm) can sell the actual energy it produces over a 10-to-20-year contract.

While the sale of this renewable energy still contributes to a larger portion of project revenues, the revenue mix has clearly shifted, and RECs cannot be considered an immaterial incentive anymore. Sure, PPAs are a stronger market signal for renewable project development, but only a couple of hundred organizations globally utilize PPAs. This makes them very challenging for businesses to access.

Through PPAs, various risks, credit needs, and long-term commitments create challenges for many organizations to meet their sustainability goals. So, while RECs do not provide as material of a market signal as PPAs, with the recent changes in market prices, RECs can now be considered a meaningful, profitable market signal for renewable projects.

Making the future of renewable energy in Texas even brighter.

------

P.J. Popovic is the CEO of Houston-based Rhythm.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn